Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine in children with neurogenic detrusor overactivity
NCT01557244Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2012
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of fesoterodine in neurogenic detrusor overactivity (NDO), sponsored by Pfizer. Started Jul 2012; status: completed.
02
Drugs
fesoterodine
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01557244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557244.